Sumit Subudhi, M.D., Ph.D. on Effective Immunotherapy in Metastatic Prostate Cancer that have Unique Markers of Immune Activation

Sumit Subudhi, M.D., Ph.D. on Effective Immunotherapy in Metastatic Prostate Cancer that have Unique Markers of Immune Activation

mdanderson

1 month
18 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer.

While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab.

“Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, M.D., Ph.D., assistant professor of Genitourinary Medical Oncology. “We found specific markers among a subset of patients with the greatest benefit, such as T-cell density and interferon-γ signaling, that may help improve our ability to select patients for treatment with checkpoint blockade.”

Read here: https://www.mdanderson.org/newsroom/immunotherapy-effective-in-metastatic-prostate-cancers-with-specific-markers-of-immune-activation.h00-159381156.html?cmpid=twitter_newsroom_prostate_immunotherapy%20_clinicaltrials_moonshots

Up Next Autoplay